Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 19 clinical trials
featured
A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis

A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis

  • 204 views
  • 08 Nov, 2020
  • 1 location
featured
Phase III, Double Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Refractory to or Intolerant of TNF Inhibitors

Phase III, Double Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Refractory to or Intolerant of TNF Inhibitors

  • 182 views
  • 25 Mar, 2021
  • 1 location
featured
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis

A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis

  • 74 views
  • 25 Mar, 2021
  • 1 location
Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis

Cost-effectiveness study of 2 disease-modifying therapies (natalizumab versus mitoxantrone followed by immunomodulator) in the management of aggressive remitting multiple sclerosis

mitoxantrone
natalizumab
disease or disorder
  • 9 views
  • 08 Nov, 2020
Cladribine Tablets After Treatment With Natalizumab (CLADRINA)

The purpose of this study is to generate hypotheses regarding the safety, efficacy, and immunological impact of cladribine tablets after treatment with natalizumab in patients with relapsing

natalizumab
natalizumab therapy
chronic progressive multiple sclerosis
secondary progressive multiple sclerosis
relapsing multiple sclerosis
  • 0 views
  • 03 Mar, 2021
  • 1 location
Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis

The purpose of this study is to evaluate if monthly natalizumab, initiated after delivery, is effective in preventing postpartum relapses.

natalizumab
  • 22 views
  • 26 Jan, 2021
  • 1 location
Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease

This research trial is designed to study the safety and effectiveness of combining the study drug, Natalizumab (Tysabri) with the standard treatment, the use of steroids, as a new treatment for

natalizumab
corticosteroids
direct bilirubin
corticosteroid therapy
steroid therapy
  • 20 views
  • 26 Jan, 2021
  • 12 locations
Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis

Rationale: Natalizumab is an effective drug in the treatment for relapsing remitting multiple sclerosis (RRMS) and is approved in the treatment regimen of 4-weekly 300mg natalizumab infusions

progressive multifocal leukoencephalopathy
natalizumab
relapsing multiple sclerosis
disease or disorder
  • 7 views
  • 24 Jan, 2021
  • 15 locations
Sub-Study: Analysis of JCV Antibody Index in MS Patients Treated With Teriflunomide - SWITCH-JCV

The purpose of this study is to determine if teriflunomide will be safe and effective to prevent relapses in patients with relapsing types of MS when switching from natalizumab to teriflunomide

MRI
natalizumab
teriflunomide
natalizumab therapy
disease or disorder
  • 0 views
  • 24 Jan, 2021
  • 3 locations
Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy

The purpose of this study is to assess the efficacy of autologous PBSCT versus FDA approved standard of care (i.e. interferon, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, or

interferon
betaseron
corticosteroids
fingolimod
gilenya
  • 120 views
  • 08 Nov, 2020
  • 1 location